Petrovax Pharm is taking part in the international pharmaceutical exhibition CPhI Worldwide-2021

Petrovax PharmPetrovax Pharm, the Russian biopharmaceutical company, will participate in CPhI Worldwide-2021 - the international specialized pharmaceutical industry exhibition. This year, it will be held from 9 to 11 November in Italy (Milan) on the territory of the largest exhibition complex Fiera Milano.

At the exhibition stand, Petrovax Pharm will present own original pharmaceutical products, that are the flagships of the product portfolio - the immunomodulator Polyoxidonium®, the enzyme preparation Longidaza®, the vaccine for the influenza prevention Grippol® plus, and a scar revision cream Imoferaza®, as well as generics and dietary supplements.

Petrovax is the largest Russian exporter of original medicines and vaccines; the products are exported to the countries of the EAEU, the Middle East, and the European Union. The company's strategy is to continue geographical expansion and search for new international partners for cooperation in the following areas: vaccine prevention, biotechnological drugs and in-licensing molecules. Petrovax is open to business collaborations with international companies in the field of biotechnology. The company is ready to acquire, license, jointly develop drugs and invest in projects aimed at treating socially significant diseases in such areas as oncology and autoimmune disorders.

CPhI Worldwide-2021 visitors are invited to be the guest of the Petrovax exposition stand # 3J63 and get acquainted with information about the company and the unique original developments of Russian scientists.

For several years CPhI Worldwide-2021 has been one of the largest business exposition platforms that unite manufacturers and suppliers of pharmaceutical products from around the world. This year it will be held on a particularly large scale - more than 170 participating countries, over 2.5 thousand companies have been announced, about 100 conferences and events will be held in the exhibition pavilions.

Petrovax Pharm is a leading Russian developer and manufacturer of medicines and vaccines with 25 years of success in the pharma market. The company holds more than 20 patents for molecules and pharmaceutical manufacturing technologies. The manufacturing unit is compliant with the Russian and international GMP standards. The company manufactures APIs and finished dosage forms. Petrovax has established itself as a reliable partner of the world pharma leaders Pfizer, Abbott, Boehringer Ingelheim, having a unique experience in transferring technologies for full-cycle manufacturing of finished dosage form of the most high-tech drugs in the world: 13-valent pneumococcal vaccine Prevenar® 13, innovative thrombolytics Actilyse® and Metalyse®. Prevenar® 13, which Petrovax Pharm manufactures and markets in partnership with the leading international company Pfizer, is among the TOP-20 best-selling medicines in the world. Since 2014, the volume of deliveries of Prevenar® 13 vaccine to the Russian market has amounted to more than 35 million doses.

About Petrovax

Petrovax is a Russian full-cycle biopharmaceutical company with 25 years of successful experience. The company is among the Top 5 immunobiological pharmaceutical manufacturers in Russia.

The product portfolio includes its own original pharmaceutical products and vaccines, localized medicinal products, as well as generics and dietary supplements.

The company has its own research center and investment program for the R&D field, Petrovax holds more than 20 new molecule and manufacturing process patents.

https://www.petrovax.com

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...